×
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

Avalo Therapeutics Earnings Date, Estimates & Call Transcripts (2022)

$0.52
+0.02 (+4.00%)
(As of 07/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.50
$0.53
50-Day Range
$0.25
$0.59
52-Week Range
$0.20
$3.43
Volume
49,357 shs
Average Volume
550,184 shs
Market Capitalization
$58.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.25

Earnings Summary

Upcoming
Earnings Date
Aug. 1Estimated
Actual EPS
(May. 5)
-$0.20 Missed By -$0.07
Consensus EPS
(May. 5)
-$0.13
Skip Charts & View Estimated and Actual Earnings Data

AVTX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

AVTX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Avalo Therapeutics Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20222($0.16)($0.12)($0.14)
Q2 20222($0.15)($0.11)($0.13)
Q3 20222($0.12)($0.10)($0.11)
Q4 20222($0.12)($0.10)($0.11)
FY 20228($0.55)($0.43)($0.49)

AVTX Earnings Date and Information

Avalo Therapeutics last posted its quarterly earnings results on May 5th, 2022. The reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by $0.07. Avalo Therapeutics has generated $0.00 earnings per share over the last year. Earnings for Avalo Therapeutics are expected to grow in the coming year, from ($0.57) to ($0.50) per share. Avalo Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 1st, 2022 based off prior year's report dates.

Avalo Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
8/1/2022
(Estimated)
        
5/5/20223/31/2022($0.13)($0.20)($0.07)
3/2/202212/31/2021($0.15)($0.16)($0.01)
11/9/20219/30/2021($0.18)($0.17)+$0.01($0.17)$1.35 million
8/2/2021Q2 2021($0.18)($0.18)($0.18)$3.36 million
5/13/2021Q1 2021($0.23)($0.32)($0.09)($0.32)$0.47 million
11/9/2020Q3 2020($0.10)($0.16)($0.06)($0.15)$1.50 million$1.11 million
8/6/2020Q2 2020($0.10)($0.15)($0.05)($0.11)$2.25 million$1.34 million
5/7/2020Q1 2020($0.12)($0.04)+$0.08$0.26$2.25 million$2.75 million
11/14/2019Q3 2019($0.17)($0.07)+$0.10($0.07)$5.15 million$5.61 million
8/8/2019Q2 2019($0.16)($0.13)+$0.03($0.15)$5.28 million$4.45 million
5/9/2019Q1 2019($0.16)($0.13)+$0.03($0.13)$4.85 million$5.41 million
11/13/2018Q3 2018($0.12)($0.26)($0.14)$0.19$4.80 million$4.08 million
8/9/2018Q2 2018($0.10)($0.10)($0.01)$4.50 million$4.79 million
5/11/2018Q1 2018($0.07)($0.07)($0.02)$4.48 million
4/2/2018Q4 2017($0.11)($0.11)($0.11)$2.23 million
11/6/2017Q3 2017($0.24)$0.52+$0.76$0.52$25.04 million
8/14/2017Q2 2017($0.26)($0.14)+$0.12($0.14)$0.16 million
5/9/2017Q1 2017($0.29)($0.19)+$0.10($0.19)$0.38 million
3/14/2017Q4 2016($0.65)($0.18)+$0.47($0.18)$0.40 million$0.18 million
11/8/2016Q3 2016($0.49)($0.70)($0.21)($0.70)$0.65 million$0.32 million
8/15/2016Q2 2016($0.56)($0.41)+$0.15($0.41)$0.65 million
5/16/2016Q1 2016($0.39)($0.59)($0.20)($0.59)
3/23/2016Q4 2015($0.53)($0.53)($0.53)
11/13/2015Q3 2015($0.15)($0.15)($0.15)












Avalo Therapeutics Earnings - Frequently Asked Questions

When is Avalo Therapeutics's earnings date?

Avalo Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 1st, 2022 based off last year's report dates. Learn more on AVTX's earnings history.

Did Avalo Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Avalo Therapeutics (NASDAQ:AVTX) missed the analysts' consensus estimate of ($0.13) by $0.07 with a reported earnings per share (EPS) of ($0.20). Learn more on analysts' earnings estimate vs. AVTX's actual earnings.

How much revenue does Avalo Therapeutics generate each year?

Avalo Therapeutics (NASDAQ:AVTX) has a recorded annual revenue of $5.40 million.

How much profit does Avalo Therapeutics generate each year?

Avalo Therapeutics (NASDAQ:AVTX) has a recorded net income of -$84.38 million. AVTX has generated $0.00 earnings per share over the last four quarters.

What is Avalo Therapeutics's EPS forecast for next year?

Avalo Therapeutics's earnings are expected to grow from ($0.57) per share to ($0.50) per share in the next year.

More Earnings Resources from MarketBeat

Upcoming Earnings:
This page (NASDAQ:AVTX) was last updated on 7/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.